Weekly Must-Read: Chinese Regulator Denies Reports of VIE Listing Ban

Exclusive: Sanpower Wins Creditor Backing for Restructuring Plan
Huarong to inject $1.25 billion as debt-laden conglomerate sets out to sell assets and repay $10 billion over eight years
Caixin Explains: What China’s First Securities Class-Action Lawsuit Means for the Stock Market
Kangmei Pharmaceutical, which is undergoing bankruptcy reorganization, was a test case for a new collective action system allowed under the amended Securities Law
- PODCAST
- MOST POPULAR



